Hertzberg 1999.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, parallel arms, flexible dose, double blind, multi‐centre BLINDING Participants: Unclear Assessors: Unclear Administrators: Unclear ALLOCATION CONCEALMENT Method: No information RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 15 DSM‐IV PTSD, 71% (10/14) war combat, mean age: 43.4 years (29‐53), 64% (9/14) male, baseline severity on SI‐PTSD: lamotrigine (44.8) and placebo (43) SCREENING Primary diagnosis: SIP Comorbidity: MINI
Interventions	Description: lamotrigine 25 mg/d ‐500mg/d (avg. max. dose: 380 mg/d) versus placebo x 8 weeks
Outcomes	ITT(LOCF) values provided. Primary outcomes: SIP, DGRP Secondary outcomes: None Data estimation: LOCF (excluded 1 patient)
Notes	INDUSTRY SUPPORT Industry funded: Yes Medication provided by industry: No Any of the authors work for industry: No ADDITIONAL INFORMATION Drop‐out rates: 27% (3/11) on lamotrigine and 75% (3/4) on placebo Quality rating score: 23
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear